TwentyTwentyTweets
-
Join 7,195 other subscribers
-
Recent Posts
Pages
Author Archives: Barbara Arzymanow
How can A&E units improve their performance?
The first point that I must make is that I do not wish to appear unappreciative or condescending. Hospital A&E work is amongst the most important that any person can undertake and many of us would find the strain unbearable. … Continue reading
Posted in A&E, Department of Health, Elderly, GPs, Hospitals, NHS, Patients
Tagged 2020health, Department of Health, elderly, General practitioner, government, GP, GPs, Hospitals, Jeremy Hunt, National Health Service, NHS, nursing, Old age, patient, Patients
Comments Off on How can A&E units improve their performance?
Hospital inspections: lessons to be learnt
The programme of independent hospital inspections carried out by the Care Quality Commission (CQC) was made tougher in September 2013. During the first year to the end of August 2014 under the new arrangements 38 NHS acute trusts (each comprising … Continue reading
Posted in A&E, Department of Health, Health and Wellbeing, Health reform, Hospitals, Local Authorities, NHS, NHS England, NHS reforms, Patient choice, Patients, Quality and Safety, safety, Uncategorized
Tagged 2020health, Care Quality Commission, Charing Cross, choice, CQC, Department of Health, Hammersmith, Hospitals, Imperial College NHS Trust, National Health Service, NHS, Quality, Queen Charlote and Chelsea, St. Mary's
Comments Off on Hospital inspections: lessons to be learnt
Threats to Mankind from Drug Resistant Bacteria and Viruses
The risk of an end to the human race may sound like science fiction. However, there are only a small number of threats that could theoretically lead to the extinction of mankind. The four main concerns that most experts share … Continue reading
Posted in Business, David Cameron, Drugs, Global Health, GPs, International, Most Significant, NHS, Pharma, Public Health, Rare conditions, Research, Vaccination
Tagged 2020health, AIDS, amoxicillin, Antibacterial, antibiotics, antiviral, Augmentin, bacteria, bacterial susceptibility, beta-lactam, beta-lactamase, bureaucracy, carpenem, cephalosporin, Ebola, end of mankind, Gilead, hepatitis, Hospitals, Human, hygiene, isolation, monobactam, NICE, pathogen, penicillin, plague, PPRS, prescribing, prevention, Prime Minister, Pseudomonas, R & D, R&D, rabies, Research, Research and development, resistance, sofosbuvir, Sovaldi, vaccine, virus, WHO
Comments Off on Threats to Mankind from Drug Resistant Bacteria and Viruses
Are pharmaceutical mega-mergers in the public interest?
The main reason for governments around the world to encourage the pharmaceutical industry is to support Research and Development – R&D – with a view to the discovery of new drugs of future benefit to mankind. Commercial pharmaceutical companies have played … Continue reading
Posted in Business, competition, Drugs, Innovation, International, Pharma, Policy, Research, Technology
Tagged 2020health, AstraZeneca, Beecham, Boots, competition, David Jack, Drugs, Glaxo, innovation, Keith Mansford, medicine, merger, Pfizer, pharmaceutical, R&D, Research, Sir David Jack, SmithKline, Smithkline Beecham, Tagamet, takeover
Leave a comment
Medical advisory body “NICE” should not spend too much time valuing drugs.
The UK National Institute for Health and Care Excellence (“NICE”) is currently holding a public consultation over its proposals for evaluating drugs. Drugs that are approved by NICE automatically become available for doctors to prescribe under the NHS throughout England … Continue reading
Posted in Business, CCGs, Commissioning, Department of Health, Drugs, Elderly, equality, Genetics, GPs, Health and Wellbeing, Health Bill, Health reform, Inequality, Innovation, Jeremy Hunt, NHS, NHS reforms, Patients, Pharma, Policy, Public Health, Research, Technology, Uncategorized, Wellbeing
Tagged 2020health, Clinical Commissioning Group, Commissioning, Department of Health, dose, elderly, General practitioner, government, GP, GPs, health, Health Bill, innovation, Jeremy Hunt, medicine, Medicines and Healthcare products Regulatory Agency, MHRA, National Health Service, National Institute for Health and Care Excellence, NHS, NICE, Old age, patient, Patients, pharmaceutical, PPRS, pricing, Proportionate QALY, Public Health, QALY, R&D, Research, value-based, value-based pricing
Leave a comment
Guest Blogspot: Negotiations with the UK Government over pharmaceutical pricing have achieved a good result for patients, the NHS and the industry.
The UK Government and the pharmaceutical industry shared many objectives throughout the recent drug pricing negotiations. For example, there was always broad agreement that: The total future drug bill needed to be affordable in the context of other spending in … Continue reading
Posted in Andrew Lansley, Business, Cancer, Department of Health, Drugs, Innovation, Jeremy Hunt, NHS, Patients, Pharma, Research, Smoking ban
Tagged 2020health, Andrew Lansley, Department of Health, Drugs, government, innovation, Jeremy Hunt, National Health Service, NHS, NICE, parallel export, parallel imporrt, patient, Patient Access Scheme, Patients, pharmaceutical, PPRS, pricing, R&D, Research, value-based, value-based pricing, VBP
1 Comment
Pharmaceutical companies must be free to determine their own research priorities: Lessons from Alzheimer’s Disease
Guest blog post from Barbara Arzymanow, Independent Healthcare Consultant Sir David Jack (1924-2011), one of history’s greatest pharmaceutical R&D directors under whom many important drugs were discovered, once told me that neither governments nor companies should overrule senior R&D management. … Continue reading
Posted in Business, Drugs, Innovation
Tagged acetylcholine, acetylcholinesterase, Alzheimer's, block-buster, British Biotech, C1-inh, cholinesterase, David Jack, glutamate, hub, innovation, marimastat, medicine, mental health, Neurochem, NICE, NMDA, pharmaceutical, R&D, Research, Sir David Jack
Leave a comment
Pharmaceutical Industry- Innovation is the only way forward.
The headline news from the Health and Social Care Information Centre (HSCIC) states that more than 1 billion prescription items were dispensed by community pharmacies in England for the first time in 2012. However, we must not be complacent about the serious … Continue reading
Guest Blogspot: Waiting for Decisions on UK Pharmaceutical Pricing
Little has been heard over how confidential talks between the Government and the pharmaceutical industry are progressing towards the goal of having a new, voluntary UK drug pricing system in place in 2014. In the eyes of the pharmaceutical companies … Continue reading
Posted in Andrew Lansley, Business, Children, Commissioning, David Cameron, Department of Health, Drugs, Emerging technologies, equality, Health and Wellbeing, Innovation, Jeremy Hunt, Uncategorized, Wellbeing
Tagged 2020health, Andrew Lansley, Bowel Cancer UK, Cancer Research UK, Drugs, government, innovation, medicine, Multiple Sclerosis Society, pharmaceutical, R&D, value-based, value-based pricing
1 Comment
Guest Blogspot: Prevention is better than cure.
The economic consequences of preventing illness are highly complex. Just comparing the costs of prevention with the direct treatment costs that should be avoided is far too simplistic. The true economic impact of preventative measures can often only be assessed … Continue reading
Posted in Alcohol, Business, Children, Elderly, Health Bill, Healthcare, Information, Jeremy Hunt, NHS, Obesity, Patient choice, Patients, Policy, Uncategorized
Tagged accidents, alcohol, Andrew Lansley, arthritis, cancer, cardiovasculsr, cause of dsath, choice, elderly, government, health, Health Bill, injury, Jeremy Hunt, longevity, mortality, National Health Service, NHS, Obesity, Patients, prevention, Public Health, respiratory, smoking, tobacco
Leave a comment
2020health's Blog 
You must be logged in to post a comment.